
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
Dr. Eric Singhi presents preliminary findings from the Phase I/II SOHO-01 trial, demonstrating that the oral HER2-targeted tyrosine kinase inhibitor BAY 2927088 achieves high response rates and durable disease control in patients with pretreated HER2-mutant NSCLC, with a manageable safety profile.
Funding supported by Bayer Pharmaceuticals. Content independently developed by OncLive.






